Tarrytown, New York (February 10, 2016) - Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the Human Vaccines Project, a public-private partnership to help discover and develop new vaccines and immunotherapies for infectious diseases and cancer.
The Human Vaccines Project brings together leading pharmaceutical and biotechnology companies, academic institutions, and government and non-profit health organizations to accelerate the development of new and improved vaccines and immunotherapies. Under the collaboration, Regeneron will provide scientific guidance and financial support for research designed to better understand the human immune response to licensed and experimental vaccines.
"At Regeneron, we are focused on turning scientific and technological expertise into improved medical outcomes," said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron. "Regeneron's unique VelociSuite® technologies may enable more predictive testing of vaccines and other immunotherapies in fully-humanized and validated in vivo models, offering the potential for more precise and efficient therapeutic development. We look forward to collaborating with other world-class scientists as part of this consortium."
The Human Vaccines Project's scientific approach includes two initiatives:
"As a long-time leader in biotechnology, Regeneron brings a science-based approach and important translational medicine capabilities to our collaboration," said Wayne C. Koff, Ph.D., Founder of the Human Vaccines Project and Chief Scientific Officer of the International AIDS Vaccine Initiative (IAVI), which incubated the Human Vaccines Project. "Given recent technological developments in genomics, bioinformatics and systems biology, we are confident that the time is right to consolidate our partners' knowledge in an innovative global consortium whose goal is to advance a new generation of vaccines and immunotherapies that could prevent or control major global diseases."
About the Human Vaccines Project The Human Vaccines Project is a non-profit public-private partnership with the mission to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers by decoding the human immune system. The Project, incubated initially at the International AIDS Vaccine Initiative (IAVI), is supported by the Robert Wood Johnson Foundation, Regeneron, GSK, Aeras, MedImmune, Sanofi Pasteur, Crucell/Janssen, Vanderbilt University Medical Center, and the John D. and Catherine T. MacArthur Foundation. The Project brings together leading academic research centers, industrial partners, nonprofits and governments to address the primary scientific barriers to developing new vaccines and immunotherapies. The Project has been endorsed by 35 of the world's leading vaccine scientists.
About Regeneron Pharmaceuticals, Inc. Regeneron (NASDAQ: REGN) is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for high LDL cholesterol, eye diseases, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including oncology, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Regeneron Forward-Looking Statements and Use of Digital Media This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation the Human Vaccines Project discussed in this news release; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates; ongoing regulatory obligations and oversight impacting Regeneron's marketed products, research and clinical programs, and business, including those relating to patient privacy; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; uncertainty of market acceptance and commercial success of Regeneron's products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; coverage and reimbursement determinations by third-party payers, including Medicare and Medicaid; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its sales or other financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare LLC, to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto. A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2014 and its Form 10-Q for the quarter ended September 30, 2015. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Contact at the Human Vaccines Project: Ted Schenkelberg, MBA/MPH, Tel. 646.441.0894 E-Mail: firstname.lastname@example.org
Media Contact at Regeneron: Alexandra Bowie, Tel. 914.847.3407 E-Mail: email@example.com